Subtype
Biliary Tract Carcinoma
CI-CAN-00001970Explore in graph →
238 active trials3 approved drugs29 evidence items
- NCIt
- C156781
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001970Explore in graph →
Clinical trials
823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (111)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03895970 | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | completed | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 |
| clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT00286013 | Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma | completed | Phase 2 | 24 | University Hospital, GhentOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03079427 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | completed | Phase 2 | 101 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03769753 | Trial of IRE in Cholangiocarcinoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03111732 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | completed | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02631590 | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04656249 | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer(LENABC) | completed | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04642664 | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer(ACABC) | completed | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT03613168 | Trastuzumab in HER2-positive Biliary Tract Cancer(BILHER) | completed | Phase 2 | 4 | Changhoon YooOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | completed | Phase 1 / Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01247337 | Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma | completed | Phase 2 | 56 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02428855 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00948935 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | completed | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02456714 | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma(4CC) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00779454 | Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | completed | Phase 2 | 72 | Vejle HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT02496741 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors(MACIST) | completed | Phase 1 / Phase 2 | 15 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT01766219 | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 17 | Wake Forest University Health SciencesOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT02053376 | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | completed | Phase 2 | 43 | Nathan Bahary, MDOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma(PrE0204) | completed | Phase 2 | 74 | PrECOG, LLC.OTHER | 2 | Oct 3, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00142480 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT01007552 | A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts | completed | Phase 2 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01206049 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations(GOC-B-P) | completed | Phase 2 | 88 | Vejle HospitalOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT00361231 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01954745 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | completed | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01718327 | A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma(SUN-CK) | completed | Phase 2 | 53 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT02468076 | Radiofrequency Ablation for Biliopancreatic Malignancy(IGNITE-1) | completed | Phase 2 | 18 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01267344 | A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC(BTC) | completed | Phase 2 | 122 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02683538 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies | completed | Phase 2 | 196 | Seoul National University HospitalOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT01692704 | Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy | completed | Phase 1 / Phase 2 | 12 | University of ZurichOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01073839 | Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma. | completed | Phase 1 / Phase 2 | 33 | University of ZurichOTHER | 1 | Sep 18, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01389414 | Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma(Vecti-BIL) | completed | Phase 2 | 89 | Prof. Massimo AgliettaOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT00504192 | A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | completed | Phase 2 | 40 | Soonchunhyang University HospitalOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT01082809 | Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma | completed | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | May 14, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Mar 29, 2023source: clinicaltrials